Axsome Therapeutics (AXSM) said Wednesday it has reached a settlement with Hikma Pharmaceuticals resolving a patent dispute over its treatment Sunosi (solriamfetol.)
The dispute arose after Hikma filed an abbreviated new drug application seeking Food and Drug Administration approval to produce a generic version of Sunosi, the company said.
As part of the agreement, Axsome said it will grant Hikma a license to launch its generic version no earlier than March 1, 2040, or Sept. 1, 2040, if pediatric exclusivity is granted, pending regulatory approval.
Axsome said the settlement will be submitted for review by the US Federal Trade Commission and the Department of Justice.
The company said similar patent litigation against other parties related to Sunosi remains pending in the US District Court for the District of New Jersey.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.